Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncoinvent ASABRRGF 36 PS Ratio is 64.17 as of Jul. 14, 2026, which is 83% below its 10-year median of 383.85. GuruFocus rates BRRGF with a GF Score™ of 36/100 and a GF Value™ of $1,432.14. The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Oncoinvent ASA ranks better than 66.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oncoinvent ASA's share price is $97.09404.
Oncoinvent ASA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.51. Hence, Oncoinvent ASA's PS Ratio for today is 64.17.
The historical rank and industry rank for Oncoinvent ASA's PS Ratio or its related term are showing as below:
BRRGF'
s PS Ratio Range Over the Past 10 Years
Min: 2.24 Med: 383.85 Max: 4678.42
Current: 4.33
During the past 11 years, Oncoinvent ASA's highest PS Ratio was 4678.42. The lowest was 2.24. And the median was 383.85.
BRRGF's PS Ratio is ranked better than 66.45% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs BRRGF: 4.33
Oncoinvent ASA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Oncoinvent ASA was 70.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -28.00% per year.
During the past 11 years, Oncoinvent ASA's highest 3-Year average Revenue per Share Growth Rate was -12.50% per year. The lowest was -68.50% per year. And the median was -40.80% per year.
Back to Basics: PS Ratio
Oncoinvent ASA (OTCPK:BRRGF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oncoinvent ASA PS Ratio Related Terms
Oncoinvent ASA PS Ratio Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncoinvent ASA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oncoinvent ASA's Share Price of today is $97.09404.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oncoinvent ASA (BRRGF) has a PS Ratio of 64.17 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncoinvent ASA and its competitors. This is 83% below median its historical median of 383.85. Over the past decade, Oncoinvent ASA's PS Ratio has ranged from 2.24 to 4,678.42. According to the industry distribution chart, Oncoinvent ASA ranks #312 out of 930 companies in the Biotechnology industry, placing it in the top 33.5%.
Is Oncoinvent ASA's PS Ratio too high?
Oncoinvent ASA's current PS Ratio of 64.17 is 83% below median its 10-year median of 383.85. Over the past 10 years, this metric has ranged from a low of 2.24 to a high of 4,678.42. The Biotechnology industry median PS Ratio is 9.41. Oncoinvent ASA's value of 64.17 is 582.3% above this industry median. Based on the distribution chart, Oncoinvent ASA ranks #312 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #312 out of 930 companies for PS Ratio. This puts Oncoinvent ASA in the upper half of its industry. The industry median PS Ratio is 9.41. Oncoinvent ASA's value of 64.17 is 582.3% above this benchmark. Historically, Oncoinvent ASA's own PS Ratio has ranged from 2.24 to 4,678.42 over the past decade. While the company's 10-year median is 383.85 vs. the industry median of 9.41, Oncoinvent ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncoinvent ASA's current PS Ratio of 64.17 is 582.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current PS Ratio is 64.17, which is 83% below median its own 10-year median of 383.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (BRRGF) has a current PS Ratio of 64.17. The stock's GF Value™ is $1,432.14, compared to a current price of $97.09 — trading 93.2% below its estimated fair value. The current PS Ratio is 64.17, which is 83% below median its 10-year median of 383.85 and 582.3% above the Biotechnology industry median of 9.41. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oncoinvent ASA (BRRGF), the current PS Ratio is 64.17 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (BRRGF) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of $97.09 is trading 93.2% below its estimated GF Value™ of $1,432.14.
Key valuation signals for BRRGF:
PS Ratio: 64.17 (83% below median its 10-year median of 383.85)
GF Value™: $1,432.14 vs. price of $97.09 (93.2% below fair value)
Industry Position: 582.3% above the Biotechnology median (#312 of 930)
No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for BRRGF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRRGF has been successfully added to your 
